DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
79.87
-0.90 (-1.11%)
Aug 1, 2025, 12:17 PM - Market open
Triumph Group Revenue
DexCom had revenue of $1.16B in the quarter ending June 30, 2025, with 15.21% growth. This brings the company's revenue in the last twelve months to $4.30B, up 9.30% year-over-year. In the year 2024, DexCom had annual revenue of $4.03B with 11.34% growth.
Revenue (ttm)
$4.30B
Revenue Growth
+9.30%
P/S Ratio
7.36
Revenue / Employee
$417,553
Employees
10,300
Market Cap
31.32B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.03B | 410.70M | 11.34% |
Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
DXCM News
- 1 day ago - 10 stocks favored to gain up to 30% in a sector that has missed this year's rally - Market Watch
- 1 day ago - DexCom, Inc. (DXCM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Dexcom beats estimates for quarterly results, names new CEO - Reuters
- 1 day ago - Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan - Business Wire
- 2 days ago - Ontario Expands Access to Dexcom G7 CGM Under the Ontario Drug Benefit (ODB) Program - Business Wire
- 4 days ago - Dexcom Launches Revolutionary AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio - Business Wire
- 9 days ago - Tenovi Expands Access to Glucose Data for Remote Patient Monitoring and Cardiometabolic Programs Through Dexcom Integration - Business Wire
- 11 days ago - DexCom: Delivering Consistent Growth - Seeking Alpha